QSAR of SARS-CoV-2 Main Protease Inhibitors Utilizing Theoretical Molecular Descriptors

被引:4
|
作者
Nandi, Sisir [1 ]
Kumar, Mohit [2 ]
Saxena, Anil Kumar [1 ]
机构
[1] Global Inst Pharmaceut Educ & Res, Dept Pharmaceut Chem, Kashipur 244713, India
[2] Vivek Coll Tech Educ, Dept Pharm, Bijnor, India
关键词
SARS-CoV-2; M-pro or 3CL(pro) main protease inhibitors; computed structural descriptors; QSAR; Anti-COVID-19 drug design; molecular descriptors; VARIABLE SELECTION; IDENTIFICATION; DESIGN; SPACE;
D O I
10.2174/1570180820666221214151614
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Background: COVID-19 is caused by a novel strain of severe acute respiratory syndrome coronaviruses (SARS-CoV-2). It has claimed casualties around the world since the end of 2019 due to its high virulence and quick multiplicity in the human body. Hence, there has been a requirement to develop effective remedial measures to mitigate the mortality. Scientists have been able to develop corona vaccines to provide immunity, but there are no specific small-molecule chemotherapeutics to combat the novel coronavirus which has spread to the whole world due to its contagiousness. In the viral genome exploration, it has been found that the main protease, also known as chymotrypsin-like cysteine protease ([M-pro] or 3C-like protease [3CL(pro)]) is responsible for the novel coronavirus replication, transcription, and host immunity destruction.Objectives: Therefore, the main protease has been selected as one of the major targets for the design of new inhibitors. The protein crystallographic and molecular docking studies on SARS-CoV-2 M-pro inhibitors and some quantitative structure-activity relationship (QSAR) studies have been carried out on SARSCoV main protease inhibitors to get some lead molecules for SARS-CoV-2 inhibition. However, there is hardly any QSAR done on the diverse data of SARS-CoV-2 main protease inhibitors. In view of it, QSAR studies have been attempted on SARS-CoV-2 M-pro inhibitors utilizing theoretical molecular descriptors solely computed from the structures of novel corona viral main protease inhibitors.Methods: As the number of structural descriptors is more than the observations, a genetic algorithm coupled with multiple linear methods has been applied for the development of QSAR models taking diverse SARS-CoV-2 M-pro inhibitors.Results: The developed best QSAR model showing R-2, Q(2) L-oo, and R-2 (pred) values of 0.7389, 0.6666, and 0.6453 respectively has been further validated on an external data set where a good correlation (r = 0.787) has been found.Conclusion: Therefore, this model may be useful for the design of new SARS-CoV-2 main protease inhibitors.
引用
收藏
页码:116 / 132
页数:17
相关论文
共 50 条
  • [1] Allosteric inhibitors of the main protease of SARS-CoV-2
    Samrat, Subodh Kumar
    Xu, Jimin
    Xie, Xuping
    Gianti, Eleonora
    Chen, Haiying
    Zou, Jing
    Pattis, Jason G.
    Elokely, Khaled
    Lee, Hyun
    Li, Zhong
    Klein, Michael L.
    Shi, Pei-Yong
    Zhou, Jia
    Li, Hongmin
    [J]. ANTIVIRAL RESEARCH, 2022, 205
  • [2] Developing inhibitors of the SARS-CoV-2 main protease
    Seitz, Christian
    Markota, Vedran
    Sztain-Pedone, Terra
    Esler, Morgan
    Moghadasi, Arad
    Kennelly, Samantha
    Demir, Ozlem
    Aihara, Hideki
    Harki, Daniel A.
    Harris, Reuben
    McCammon, J. Andrew
    Amaro, Rommie E.
    [J]. BIOPHYSICAL JOURNAL, 2022, 121 (03) : 192A - 192A
  • [3] Potential SARS-CoV-2 main protease inhibitors
    Banerjee, Riddhidev
    Perera, Lalith
    Tillekeratne, L. M. Viranga
    [J]. DRUG DISCOVERY TODAY, 2021, 26 (03) : 804 - 816
  • [4] On the origins of SARS-CoV-2 main protease inhibitors
    Janin, Yves L.
    [J]. RSC MEDICINAL CHEMISTRY, 2024, 15 (01): : 81 - 118
  • [5] Perspectives on SARS-CoV-2 Main Protease Inhibitors
    Gao, Kaifu
    Wang, Rui
    Chen, Jiahui
    Tepe, Jetze J.
    Huang, Faqing
    Wei, Guo-Wei
    [J]. JOURNAL OF MEDICINAL CHEMISTRY, 2021, 64 (23) : 16922 - 16955
  • [6] Molecular Docking Unveils Prospective Inhibitors for the SARS-COV-2 Main Protease
    Ahmad, Fawad
    Ikram, Saima
    Ahmad, Jamshaid
    Rehman, Irshad Ur
    Khattak, Saeed Ullah
    Butt, Sadia
    Mushtaq, Maryam
    [J]. SAINS MALAYSIANA, 2021, 50 (05): : 1473 - 1484
  • [7] Discovery of novel inhibitors of SARS-CoV-2 main protease
    Zheng, Lei
    Chen, Yanmei
    Bao, Jingxiao
    He, Liping
    Dong, Suzhen
    Qi, Yifei
    Zhang, John Z. H.
    [J]. JOURNAL OF BIOMOLECULAR STRUCTURE & DYNAMICS, 2022, 40 (23): : 12526 - 12534
  • [8] Discovery and Mechanism of SARS-CoV-2 Main Protease Inhibitors
    Huff, Sarah
    Kummetha, Indrasena Reddy
    Tiwari, Shashi Kant
    Huante, Matthew B.
    Clark, Alex E.
    Wang, Shaobo
    Bray, William
    Smith, Davey
    Carlin, Aaron F.
    Endsley, Mark
    Rana, Tariq M.
    [J]. JOURNAL OF MEDICINAL CHEMISTRY, 2022, 65 (04) : 2866 - 2879
  • [9] Potent and biostable inhibitors of the main protease of SARS-CoV-2
    Tsuji, Kohei
    Ishii, Takahiro
    Kobayakawa, Takuya
    Higashi-Kuwata, Nobuyo
    Azuma, Chika
    Nakayama, Miyuki
    Onishi, Takato
    Nakano, Hiroki
    Wada, Naoya
    Hori, Miki
    Shinohara, Kouki
    Miura, Yutaro
    Kawada, Takuma
    Hayashi, Hironori
    Hattori, Shin-ichiro
    Bulut, Haydar
    Das, Debananda
    Takamune, Nobutoki
    Kishimoto, Naoki
    Saruwatari, Junji
    Okamura, Tadashi
    Nakano, Kenta
    Misumi, Shogo
    Mitsuya, Hiroaki
    Tamamura, Hirokazu
    [J]. ISCIENCE, 2022, 25 (11)
  • [10] Fullerene derivatives as inhibitors of the SARS-CoV-2 main protease
    Katagishi, Daiki
    Yasuda, Daisuke
    Takahashi, Kyoko
    Nakamura, Shigeo
    Mashino, Tadahiko
    Ohe, Tomoyuki
    [J]. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2023, 80